Abstract
Background For a patient with Hereditary Angioedema (HAE), physiological and/or psychological stress can cause insufficient control of local inflammatory pathways. This leads to complement and contact system activation and excess bradykinin resulting in angioedema. Therefore, an invasive procedure or surgery can trigger an HAE attack; this in turn can cause further medical complications and pose an added danger to the post-procedure patient. C1 inhibitor, Berinert, was approved in the US and Canada in 2009 and 2010, respectively, for the treatment of acute attacks. In April 2013, Berinert was approved in Europe for short-term prophylaxis prior to medical, dental, or surgical procedures to prevent HAE attacks. Currently, Berinert is not approved in Canada or the US for prophylaxis. We aim to demonstrate the effectiveness of C1 esterase inhibitor, Berinert, as a prophylactic treatment for HAE patients undergoing invasive procedures.
Highlights
For a patient with Hereditary Angioedema (HAE), physiological and/or psychological stress can cause insufficient control of local inflammatory pathways. This leads to complement and contact system activation and excess bradykinin resulting in angioedema
In April 2013, Berinert® was approved in Europe for short-term prophylaxis prior to medical, dental, or surgical procedures to prevent HAE attacks
We aim to demonstrate the effectiveness of C1 esterase inhibitor, Berinert®, as a prophylactic treatment for HAE
Summary
For a patient with Hereditary Angioedema (HAE), physiological and/or psychological stress can cause insufficient control of local inflammatory pathways. This leads to complement and contact system activation and excess bradykinin resulting in angioedema. An invasive procedure or surgery can trigger an HAE attack; this in turn can cause further medical complications and pose an added danger to the post-procedure patient. C1 inhibitor, Berinert®, was approved in the US and Canada in 2009 and 2010, respectively, for the treatment of acute attacks. In April 2013, Berinert® was approved in Europe for short-term prophylaxis prior to medical, dental, or surgical procedures to prevent HAE attacks. We aim to demonstrate the effectiveness of C1 esterase inhibitor, Berinert®, as a prophylactic treatment for HAE patients undergoing invasive procedures
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
